These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 34694788)
41. Negative values and variance functions: Implications for statistical analysis. Sadler WA Ann Clin Biochem; 2021 Sep; 58(5):395-399. PubMed ID: 33334133 [TBL] [Abstract][Full Text] [Related]
42. An Accurate Substitution Method To Minimize Left Censoring Bias in Serum Steroid Measurements. Handelsman DJ; Ly LP Endocrinology; 2019 Oct; 160(10):2395-2400. PubMed ID: 31199478 [TBL] [Abstract][Full Text] [Related]
43. Testing for differences in changes in the presence of censoring: parametric and non-parametric methods. Wu MC; Hunsberger S; Zucker D Stat Med; 1994 Mar 15-Apr 15; 13(5-7):635-46. PubMed ID: 8023039 [TBL] [Abstract][Full Text] [Related]
45. Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer. Bagust A; Beale SJ Med Decis Making; 2018 Oct; 38(7):789-796. PubMed ID: 30125510 [TBL] [Abstract][Full Text] [Related]
46. Research considerations: power analysis and effect size. Connelly LM Medsurg Nurs; 2008 Feb; 17(1):41-2. PubMed ID: 18429540 [No Abstract] [Full Text] [Related]
47. How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring? McNamee R Stat Med; 2017 Sep; 36(21):3315-3333. PubMed ID: 28621000 [TBL] [Abstract][Full Text] [Related]
48. Causal inference in tuberculosis treatment studies: bias considerations and data needs. Franke MF; Rodriguez CA; Mitnick CD Int J Tuberc Lung Dis; 2019 Aug; 23(8):960-961. PubMed ID: 31533889 [No Abstract] [Full Text] [Related]
52. Evaluation of Statistical Treatments of Left-Censored Environmental Data Using Coincident Uncensored Data Sets. II. Group Comparisons. Antweiler RC Environ Sci Technol; 2015 Nov; 49(22):13439-46. PubMed ID: 26490190 [TBL] [Abstract][Full Text] [Related]
53. Simulating survival data with predefined censoring rates for proportional hazards models. Wan F Stat Med; 2017 Feb; 36(5):838-854. PubMed ID: 27873333 [TBL] [Abstract][Full Text] [Related]
54. Analysis of censored exposure data by constrained maximization of the Shapiro-Wilk W statistic. Flynn MR Ann Occup Hyg; 2010 Apr; 54(3):263-71. PubMed ID: 19955326 [TBL] [Abstract][Full Text] [Related]
55. Artefacts, biology and bias in museum collection research. Wehi PM; Whaanga H; Trewick SA Mol Ecol; 2012 Jul; 21(13):3103-9. PubMed ID: 22916347 [TBL] [Abstract][Full Text] [Related]
56. Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. Kuehne F; Jahn B; Conrads-Frank A; Bundo M; Arvandi M; Endel F; Popper N; Endel G; Urach C; Gyimesi M; Murray EJ; Danaei G; Gaziano TA; Pandya A; Siebert U J Comp Eff Res; 2019 Sep; 8(12):1013-1025. PubMed ID: 31512926 [No Abstract] [Full Text] [Related]
57. The design and analysis of state-trace experiments. Prince M; Brown S; Heathcote A Psychol Methods; 2012 Mar; 17(1):78-99. PubMed ID: 22040373 [TBL] [Abstract][Full Text] [Related]
58. Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment. Schimetta W; Poelz G; Poelz W; Haring HP; Aichner F Arthritis Res Ther; 2004 Nov; 7(1):E2. PubMed ID: 15642128 [No Abstract] [Full Text] [Related]
59. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers. Steele R; Hudson M Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312 [No Abstract] [Full Text] [Related]
60. Effects of censored variables on family studies. van den Oord EJ; Rowe DC Behav Genet; 1997 Mar; 27(2):99-112. PubMed ID: 9145548 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]